LOGIN  |  REGISTER
Terns Pharmaceuticals

List of Medical Device Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 592.64
8.56 1.47
2.57M
356.18M
US$ 211.090B
US$ 113.48
-1.51 -1.31
6.15M
1.73B
US$ 196.320B
US$ 383.42
1.63 0.43
1.67M
381.22M
US$ 146.170B
US$ 98.66
0.49 0.50
6.71M
1.47B
US$ 145.030B
US$ 88.08
0.92 1.06
8.75M
1.28B
US$ 112.740B
US$ 237.38
1.08 0.46
1.95M
290.01M
US$ 68.840B
US$ 84.37
0.23 0.27
1.00M
494.60M
US$ 41.730B
US$ 69.78
-0.08 -0.11
4.91M
589.80M
US$ 41.160B
US$ 239.78
2.65 1.12
686,846
146.80M
US$ 35.200B
US$ 336.34
-0.86 -0.26
523,121
72.42M
US$ 24.360B
US$ 109.56
0.62 0.57
1.03M
199.07M
US$ 21.810B
US$ 209.62
-0.53 -0.25
664,074
98.71M
US$ 20.690B
US$ 275.81
2.95 1.08
514,984
70.14M
US$ 19.350B
US$ 93.27
1.23 1.34
1.91M
199.58M
US$ 18.610B
US$ 69.73
-0.24 -0.34
6.09M
226.94M
US$ 15.820B
US$ 30.98
0.03 0.10
3.75M
510.59M
US$ 15.820B
US$ 25.29
0.24 0.96
2.04M
435.99M
US$ 11.030B
US$ 90.80
0.33 0.36
1.83M
113.74M
US$ 10.330B
US$ 263.69
1.38 0.53
426,000
38.38M
US$ 10.120B
US$ 172.29
2.35 1.38
567,441
53.54M
US$ 9.220B
US$ 160.51
-2.34 -1.44
717,698
56.03M
US$ 8.990B
US$ 56.88
-2.13 -3.61
1.25M
151.60M
US$ 8.620B
US$ 156.39
-0.12 -0.08
519,295
55.14M
US$ 8.620B
US$ 181.27
-0.18 -0.10
575,369
46.44M
US$ 8.420B
US$ 342.41
-2.06 -0.60
119,114
22.92M
US$ 7.850B
US$ 17.40
-0.04 -0.23
704,918
352.16M
US$ 6.130B
US$ 102.90
0.83 0.81
957,708
58.28M
US$ 6.000B
US$ 177.68
3.85 2.21
512,879
29.97M
US$ 5.330B
US$ 141.00
0.44 0.31
136,516
33.54M
US$ 4.730B
US$ 79.55
0.15 0.19
2.25M
58.54M
US$ 4.660B
US$ 76.02
-2.82 -3.58
964,830
54.11M
US$ 4.110B
US$ 163.87
-2.20 -1.32
215,634
24.48M
US$ 4.010B
US$ 73.49
-0.04 -0.05
516,272
50.22M
US$ 3.690B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 108.33
1.34 1.25
451,435
31.30M
US$ 3.390B
US$ 26.17
0.15 0.58
1.15M
108.20M
US$ 2.830B
US$ 48.30
0.32 0.67
440,354
54.30M
US$ 2.620B
US$ 24.58
-1.64 -6.25
2.52M
101.66M
US$ 2.500B
US$ 52.63
-0.37 -0.70
364,827
45.69M
US$ 2.400B
US$ 35.15
-2.38 -6.34
1.86M
65.68M
US$ 2.310B
US$ 99.06
0.83 0.84
113,586
22.48M
US$ 2.230B
US$ 67.69
0.83 1.24
385,969
30.89M
US$ 2.090B
US$ 57.20
-0.82 -1.41
2.61M
33.56M
US$ 1.920B
US$ 38.47
0.83 2.21
893,523
48.75M
US$ 1.880B
US$ 24.10
0.86 3.70
574,891
77.16M
US$ 1.860B
US$ 11.57
0.28 2.48
1.05M
141.77M
US$ 1.640B
US$ 10.52
0.14 1.35
572,222
134.56M
US$ 1.420B
US$ 9.12
0.04 0.44
464,896
146.95M
US$ 1.340B
US$ 30.72
-0.52 -1.66
430,232
41.92M
US$ 1.290B
US$ 16.79
0.22 1.33
904,912
76.25M
US$ 1.280B
US$ 30.39
-0.79 -2.53
613,115
40.30M
US$ 1.220B
US$ 26.14
-0.31 -1.17
138,130
46.39M
US$ 1.210B
US$ 22.85
-0.06 -0.26
142,214
49.60M
US$ 1.130B
US$ 22.29
0.43 1.97
469,732
49.28M
US$ 1.100B
US$ 17.61
-0.03 -0.17
92,506
61.52M
US$ 1.080B
US$ 34.56
-0.08 -0.23
593,116
28.76M
US$ 993.950M
US$ 10.88
0.22 2.06
694,295
83.72M
US$ 910.870M
US$ 18.09
-0.34 -1.84
491,424
44.01M
US$ 796.140M
US$ 59.17
0.81 1.39
48,652
12.67M
US$ 749.680M
US$ 15.92
-0.13 -0.81
283,094
45.96M
US$ 731.680M
US$ 5.46
-0.03 -0.55
681,068
128.81M
US$ 703.300M
US$ 16.69
-0.23 -1.36
284,749
41.94M
US$ 699.980M
US$ 18.13
0.20 1.12
95,101
38.21M
US$ 692.750M
US$ 3.67
-0.21 -5.41
1.96M
186.64M
US$ 684.970M
US$ 27.16
0.63 2.37
216,609
24.22M
US$ 657.820M
US$ 10.04
-0.07 -0.69
358,513
65.37M
US$ 656.310M
US$ 64.68
6.44 11.06
475,808
9.27M
US$ 599.580M
US$ 17.42
0.02 0.11
392,359
33.60M
US$ 585.310M
US$ 13.52
-0.15 -1.10
297,612
41.23M
US$ 557.430M
US$ 8.71
0.46 5.58
383,942
62.30M
US$ 542.630M
US$ 4.94
0.19 4.00
638,996
105.48M
US$ 521.070M
US$ 12.43
-0.34 -2.66
543,617
40.63M
US$ 505.030M
US$ 0.85
-0.03 -3.09
19.03M
595.33M
US$ 504.840M
US$ 8.41
0.07 0.84
3.14M
58.52M
US$ 492.150M
US$ 14.33
0.66 4.83
543,546
33.02M
US$ 473.180M
US$ 17.62
0.32 1.85
286,978
24.26M
US$ 427.460M
US$ 17.40
-0.03 -0.17
137,599
24.00M
US$ 417.600M
US$ 10.85
-0.06 -0.55
104,791
37.43M
US$ 406.120M
US$ 14.29
0.24 1.71
109,881
27.60M
US$ 394.400M
US$ 11.97
0.06 0.50
83,467
29.85M
US$ 357.300M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 8.87
0.05 0.57
1.26M
38.52M
US$ 341.670M
US$ 8.15
-0.02 -0.24
147,415
38.94M
US$ 317.360M
US$ 34.00
0.13 0.38
132,907
8.46M
US$ 287.640M
US$ 32.64
-0.07 -0.21
25,406
8.74M
US$ 285.270M
US$ 3.65
-0.07 -1.88
519,370
74.59M
US$ 272.250M
US$ 10.47
-0.05 -0.48
149,548
23.82M
US$ 249.400M
US$ 6.26
-0.14 -2.19
136,783
39.49M
US$ 247.210M
US$ 7.68
-0.19 -2.41
58,628
31.85M
US$ 244.610M
US$ 3.43
0.27 8.54
2.36M
67.59M
US$ 231.830M
US$ 27.00
0.66 2.51
800
8.53M
US$ 230.310M
US$ 8.65
0.11 1.29
176,558
26.22M
US$ 226.800M
US$ 2.24
-0.06 -2.61
363,780
100.56M
US$ 225.250M
US$ 7.35
-0.08 -1.08
58,814
30.03M
US$ 220.720M
US$ 62.16
0.17 0.27
15,118
3.39M
US$ 210.720M
US$ 6.10
-0.05 -0.81
479,584
33.70M
US$ 205.570M
US$ 10.23
-0.09 -0.87
47,014
18.81M
US$ 192.430M
US$ 2.93
-0.19 -6.09
279,427
64.80M
US$ 189.860M
US$ 4.08
0.08 2.00
192,195
45.84M
US$ 187.030M
US$ 2.08
-0.02 -0.95
388,105
84.73M
US$ 176.240M
US$ 4.57
0.07 1.56
384,986
37.47M
US$ 171.240M
US$ 7.98
-0.06 -0.75
89,754
21.26M
US$ 169.650M
US$ 4.93
0.10 2.07
7,071
30.49M
US$ 150.320M
US$ 44.35
0.02 0.05
31,604
3.26M
US$ 144.580M
US$ 0.92
-0.04 -4.19
157,847
156.55M
US$ 144.030M
US$ 2.83
-0.01 -0.35
691,106
50.40M
US$ 142.630M
US$ 2.82
0.06 2.17
349,245
49.56M
US$ 139.760M
US$ 3.02
0.09 3.07
243,534
43.09M
US$ 130.130M
US$ 6.53
-0.20 -2.97
155,658
16.39M
US$ 107.030M
US$ 2.69
0.03 1.13
45,948
39.39M
US$ 105.960M
US$ 15.90
0.20 1.27
201,461
6.55M
US$ 104.140M
US$ 2.98
0.08 2.76
1.33M
34.82M
US$ 103.760M
US$ 3.20
-0.01 -0.31
13,972
30.25M
US$ 96.800M
US$ 8.32
-0.25 -2.92
43,026
11.61M
US$ 96.600M
US$ 15.22
-0.06 -0.39
17,099
6.27M
US$ 95.430M
US$ 1.20
0.02 1.69
515,927
77.89M
US$ 93.470M
US$ 2.57
0.03 1.18
38,216
34.31M
US$ 88.180M
US$ 1.93
0.01 0.52
132,062
43.62M
US$ 84.190M
US$ 15.85
1.59 11.15
52,376
5.25M
US$ 83.210M
US$ 2.17
-0.03 -1.36
51,774
37.10M
US$ 80.510M
US$ 0.54
0.03 5.22
27,490
139.01M
US$ 75.620M
US$ 2.72
0.04 1.64
42,864
26.08M
US$ 71.040M
US$ 1.18
-0.03 -2.48
67,784
59.23M
US$ 69.890M
US$ 4.26
-0.06 -1.39
42,375
16.04M
US$ 68.330M
US$ 1.21
-0.01 -0.82
294,100
55.50M
US$ 67.160M
C$ 0.27
0.01 3.85
129,524
247.78M
C$ 66.900M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 0.14
0.0039 2.78
373,073
417.59M
US$ 60.130M
US$ 3.31
0.13 4.09
48,383
17.54M
US$ 58.060M
US$ 0.98
0.0076 0.78
71,354
57.89M
US$ 56.670M
US$ 1.03
-0.01 -0.96
59,575
54.95M
US$ 56.600M
US$ 1.39
-0.03 -2.11
15,881
37.64M
US$ 52.320M
US$ 0.84
-0.004 -0.47
119,770
59.34M
US$ 50.020M
US$ 19.70
0.00 0.00
0
2.53M
US$ 49.840M
US$ 1.21
-0.01 -0.82
20,031
40.14M
US$ 48.570M
US$ 1.23
0.03 2.50
406,114
37.72M
US$ 46.400M
C$ 0.38
0.05 13.64
20,649
119.77M
C$ 44.910M
C$ 0.47
0.02 3.33
4,500
93.38M
C$ 43.420M
US$ 3.16
0.00 0.00
415,546
13.30M
US$ 42.030M
US$ 0.79
-0.03 -3.45
965,765
52.54M
US$ 41.510M
US$ 1.96
-0.12 -5.77
615,769
20.75M
US$ 40.670M
US$ 5.63
2.52 81.03
9,302
6.63M
US$ 37.330M
C$ 0.33
-0.005 -1.52
11,000
113.10M
C$ 36.760M
C$ 0.45
-0.03 -6.25
12,800
77.42M
C$ 34.840M
US$ 5.74
-0.21 -3.53
629,010
5.89M
US$ 33.810M
US$ 1.06
0.02 1.91
201,572
30.84M
US$ 32.690M
US$ 1.41
-0.09 -6.00
32,762
20.24M
US$ 28.540M
US$ 1.64
-0.14 -7.87
2.41M
16.93M
US$ 27.770M
US$ 1.66
0.03 1.84
25,472
16.64M
US$ 27.620M
US$ 0.38
0.0058 1.55
3.58M
72.19M
US$ 27.430M
US$ 1.11
0.00 0.00
33,337
22.90M
US$ 25.420M
US$ 3.56
-0.05 -1.39
30,327
6.79M
US$ 24.170M
US$ 0.79
0.0043 0.55
49,127
29.94M
US$ 23.590M
US$ 1.16
-0.02 -1.69
186,540
17.23M
US$ 19.990M
US$ 1.06
0.00 0.00
436,612
18.50M
US$ 19.610M
US$ 0.93
0.08 9.41
4,622
20.63M
US$ 19.190M
C$ 0.07
0.00 0.00
0
270.17M
C$ 18.910M
C$ 0.08
-0.005 -5.88
99,494
217.73M
C$ 17.420M
US$ 1.56
-0.09 -5.24
5,575
10.54M
US$ 16.440M
C$ 0.10
0.00 0.00
65,500
159.67M
C$ 15.970M
C$ 0.04
-0.005 -12.50
243,000
451.63M
C$ 15.810M
US$ 1.64
-0.17 -9.39
402,153
8.81M
US$ 14.450M
US$ 0.65
-0.04 -5.64
620,115
22.00M
US$ 14.340M
US$ 2.91
-0.05 -1.69
4,063
4.17M
US$ 12.130M
US$ 0.64
-0.07 -9.35
11.42M
16.82M
US$ 10.760M
US$ 0.33
0.01 3.34
196,774
31.90M
US$ 10.370M
US$ 0.49
0.09 22.41
555,962
20.19M
US$ 9.890M
US$ 0.66
-0.05 -7.07
1.23M
13.96M
US$ 9.270M
US$ 0.12
0.00 0.00
0
73.90M
US$ 8.870M
US$ 0.35
-0.06 -15.30
8,542
24.39M
US$ 8.560M
US$ 4.05
0.12 3.05
1,201
2.04M
US$ 8.260M
US$ 1.21
-0.13 -9.70
329,151
6.67M
US$ 8.070M
US$ 1.27
0.00 0.00
0
6.24M
US$ 7.920M
US$ 1.75
0.04 2.34
148,226
4.46M
US$ 7.800M
US$ 0.65
0.0052 0.81
53,895
11.07M
US$ 7.200M
C$ 0.12
-0.02 -14.29
387,495
59.81M
C$ 7.180M
US$ 1.39
0.08 6.11
47,509
4.39M
US$ 6.100M
US$ 0.48
0.07 16.34
500
11.88M
US$ 5.670M
US$ 1.79
0.01 0.56
38,250
3.14M
US$ 5.620M
US$ 1.21
0.13 11.52
410,754
4.37M
US$ 5.290M
US$ 0.31
0.00 0.00
0
15.85M
US$ 4.920M
US$ 1.85
-0.03 -1.60
20,400
2.05M
US$ 3.790M
US$ 0.44
-0.03 -5.81
216,684
8.00M
US$ 3.500M
US$ 1.90
0.00 0.00
0
1.82M
US$ 3.460M
US$ 3.47
0.15 4.36
10,077
980,321
US$ 3.400M
US$ 4.52
-0.15 -3.21
21,154
729,980
US$ 3.300M
US$ 0.75
-0.05 -6.60
385,744
3.73M
US$ 2.800M
US$ 0.36
-0.007 -1.89
130,982
7.26M
US$ 2.640M
US$ 0.29
0.02 7.69
250,675
8.27M
US$ 2.430M
US$ 0.96
0.0019 0.20
28,042
2.46M
US$ 2.360M
US$ 0.21
-0.03 -12.50
45,320
10.59M
US$ 2.220M
US$ 0.02
0.00 0.00
0
96.71M
US$ 2.030M
US$ 0.60
0.01 1.71
194,981
3.20M
US$ 1.920M
US$ 0.50
-0.02 -3.81
522,204
3.75M
US$ 1.880M
US$ 3.34
-0.21 -5.94
21,743
552,854
US$ 1.850M
US$ 0.05
0.00 0.00
0
29.91M
US$ 1.500M
US$ 3.50
3.27 1.00
2,602
418,049
US$ 1.460M
US$ 0.12
0.00 0.00
0
7.26M
US$ 878K
US$ 0.15
0.00 0.00
0
5.24M
US$ 796K
US$ 0.41
0.00 0.00
0
1.78M
US$ 730K
US$ 0.85
0.00 0.00
60,097
-
US$ -
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
-0.0003 -100.00
136.41M
855.04M
US$ -
US$ 6.06
0.00 0.00
16,151
-
US$ -
US$ 26.53
0.00 0.00
110,815
-
US$ -
C$ 0.80
0.00 0.00
3,002
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Device Stocks


Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line

RA'ANANA, ISRAEL, Jan. 17, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced that the Company is establishing a dedicated production line for a crucial component of its innovative respiratory support system, in collaboration with Zriha Medical Ltd ("Zriha Medical"), a leading international manufacturer specializing in medical device production. The... Read more


Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure Device post cardiac ablation in both concomitant and sequential procedures MARLBOROUGH, Mass., Jan. 16, 2025... Read more


Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the United States Patent and Trademark Office (“USPTO”)... Read more


United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel® Prostate Specific Antigen (PSA) Screening Test has received approval from the United Arab Emirates Ministry of Health... Read more


Masimo Announces Select Preliminary 2024 Financial Results and 2025 Guidance

Complete fourth quarter and full-year 2024 financial results will be announced on Tuesday, February 25, 2025 IRVINE, Calif. / Jan 16, 2025 / Business Wire / Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 28, 2024 and provided estimates for its full-year 2025 guidance. Preliminary Fourth Quarter 2024 Financial Results: Consolidated revenue is expected to be approximately $601... Read more


Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay

Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the... Read more


Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2024 Results

SUNNYVALE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2024 financial results ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Financial and Operational Highlights Fourth quarter 2024 worldwide da Vin... Read more


Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024. Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek’s 2023 revenue of $193.0 million. This included a negative foreign exchange impact of approximately $1.0 million. Expected... Read more


Becton Dickinson Boosts U.S. Manufacturing of Critical Medical Devices

FRANKLIN LAKES, N.J., Jan. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional investments in its U.S. manufacturing network to add capacity for critical medical devices, including syringes, needles and IV catheters, to meet the ongoing needs of the nation's health care system. As part of the company's 2024 investment of more than $10 million to expand manufacturing capacity,... Read more


Biomerica Reports Second Quarter Fiscal 2025 Financial Results

Total Revenue Increases 5% Year-Over-Year Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2025 ended November 30, 2024. Key Highlights: Direct-to-Consumer Launch of inFoods® IBS TestPatients... Read more


Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue

Fourth quarter 2024 total revenue expected to be a record at approximately $8.2 million, representing growth of approximately 30% compared to the prior-year period. Fourth quarter 2024 recurring revenue expected to be approximately $4.2 million, representing growth of approximately 27% compared to the prior-year period. Full year 2024 total revenue expected to be approximately $28.1 million, representing growth of approximately 25% compared to the prior year. Full... Read more


Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

ALISO VIEJO, Calif. / Jan 14, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform, including: In a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials, iDose TR (travoprost... Read more


908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Full year 2024 reported revenue growth of at least 15% compared to 2023 BOSTON / Jan 14, 2025 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2024. Preliminary unaudited revenue for the fourth quarter of 2024 is expected to be approximately $17.2 million, compared to $14.4 million in... Read more


Inspira Technologies Unveils Modular Configuration for Revolutionary VORTX™ Blood Oxygenation Delivery Technology

The technology has the potential to provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually RA'ANANA, Israel, Jan. 14, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, is proud to announce the development of a modular configuration for its groundbreaking VORTX blood oxygenation delivery technology. We... Read more


Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024. Select Preliminary Financial Highlights Fourth quarter 2024 total... Read more


Elutia Announces Full Launch of EluPro Following Strong Initial Demand

First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, announced the U.S. commercial launch of EluPro™, the first and only FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators... Read more


Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024

MOUNTAIN VIEW, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended December 28, 2024. Fourth Quarter 2024 Results The Company’s strategic review remains ongoing with multiple... Read more


Allurion Technologies Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

NATICK, Mass. / Jan 14, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in... Read more


NuGen Medical Devices Announces the Appointment of Liang Lin as Chief Executive Officer

Toronto, Ontario--(Newsfile Corp. - January 14, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce the appointment of Mr. Liang Lin as the new Chief Executive Officer of NuGen. Liang is the founder and CEO of Sol-Millennium Medical Group ("SolM"), an organization committed to transforming the medical device sector through innovative approaches... Read more


Merit Medical Systems Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on...

2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year 2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year 2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable... Read more


Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included... Read more


Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national... Read more


Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 ACTON, Mass. / Jan 13, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available... Read more


Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

GOLETA, Calif. / Jan 13, 2025 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth... Read more


OrthoPediatrics Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance

Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year Initiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended... Read more


Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved...

MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA). With these approvals medical care teams can provide patients in China the most advanced Accuray radiation therapy solutions. The CyberKnife S7 System is the latest generation CyberKnife platform and the introduction of the... Read more


Alphatec Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook

Full-year 2024 total revenue grew 27% to approximately $611 million Expect full-year 2025 total revenue of $732 million and positive free cash flow CARLSBAD, Calif. / Jan 13, 2025 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31, 2024. The Company also provided a financial... Read more


SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024

Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26% Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024. Fourth Quarter 2024 Summary (any comparisons... Read more


BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations

Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash., Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter... Read more


Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results

Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif., Jan. 13, 2025  /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2024 revenue and other financial results. Preliminary, Unaudited... Read more


FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

Study to be conducted under $3.6 million NIH grant  DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the safety and initial efficacy of SeaStar... Read more


Butterfly Network and Rutgers Robert Wood Johnson Medical School Reveal Preliminary Findings from Seminal Study on Impact of POCUS in Hospital Care

Study demonstrates significant reductions in length of stay and healthcare costs, advocating for broader adoption of POCUS in hospital settings. BURLINGTON, Mass. & NEW YORK / Jan 13, 2025 / Business Wire / Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound today announced preliminary findings from a seminal study conducted by Rutgers Robert Wood Johnson Medical... Read more


AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment. LATHAM, N.Y. / Jan 13, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality... Read more


Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024

ENGLEWOOD, Colo. / Jan 13, 2025 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024. Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a range of $71.5 to $71.8 million, representing reported... Read more


AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

MASON, Ohio / Jan 13, 2025 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason,... Read more


Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million QUEENSBURY, N.Y. / Jan 13, 2025 / Business Wire / Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024. Preliminary Fourth Quarter... Read more


KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter

MAHWAH, N.J. / Jan 13, 2025 / Business Wire / KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. Financial Results (unaudited) Preliminary, unaudited fourth... Read more


Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results

Expects Record Revenues for the Fourth Quarter of 2024 SAN RAFAEL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the quarter ended December 31, 2024. Total revenue for the fourth quarter of 2024 is estimated to be in the range of $5.0 million to $5.1 million, which is expected... Read more


Treace Medical Concepts Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue... Read more


CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35% Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30% Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, representing growth of 23% to 27% MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited... Read more


Apyx Medical Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Revenue Summary Total revenue expected to be in a range of approximately $14.1 to $14.3 million, representing a... Read more


Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission MIAMI / Jan 13, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA... Read more


Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb’s expanding clinical-stage pipeline. “We’re focused on finding... Read more


Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 BAAR, Switzerland / Jan 13, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working... Read more


EDAP TMS Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures

Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems  Record U.S. Fourth Quarter Focal One System Sales Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30% AUSTIN, Texas, January 13, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the fourth quarter of calendar... Read more


Inspire Medical Systems Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance

MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024, and provided its initial full year 2025 revenue guidance... Read more


Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union

VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are designed for a broader depth of focus*, with the proven... Read more


MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Unaudited Fourth Quarter and Full Year 2024 Results Core revenue... Read more


CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering

Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that the Company closed the subscription... Read more


Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's...

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier... Read more